News & Events

07 October 2020 Lilly provides comprehensive update on progress of SARS-CoV-2 neutralizing antibody programs

Eli Lilly and Company (NYSE: LLY) today announced additional details on its SARS-CoV-2 neutralizing antibody programs – including interim data on combination therapy in recently diagnosed patients with mild-to-moderate COVID-19 – and plans to make these therapies broadly available to patients.

Read More

05 October 2020 Cary man shares his battle with COVID-19

I was at the point where I didn't think I was going to make it. I was really bad, suffering with the breathing and everything...

Read More

27 September 2020 Medicine faculty part of ACTIV-3 trial team lauded by NIH

A team of Duke Health clinicians that include faculty from the Department of Medicine are working diligently in a collaborative effort to enroll patients in a randomized, controlled trial, testing a novel antibody treatment for COVID-19.

Read More

25 September 2020 Duke Tests Novel COVID-19 Therapy, Is Lead Enroller in International Trial

The early stage of COVID-19 offers a critical window of opportunity to prevent the progression of the disease to the acute state, when patients require supportive care. By targeting the SARS-CoV-2 virus early on, a therapeutic can help to quickly eliminate the virus from the body while the patient’s symptoms are mild.

Read More

23 September 2020 COVID-19: An Update on the Federal Response

Chairman Alexander, Ranking Member Murray and distinguished members of Committee. It is an honor to appear before you today to discuss the Department of Health and Human Services’ ongoing response to the COVID-19 pandemic.

Read More

17 September 2020 HCS to lead state effort to raise awareness about COVID-19 in underserved communities

The University of North Texas Health Science Center at Fort Worth (HSC) will administer the Texas portion of a $12 million National Institutes of Health award for outreach and engagement efforts in ethnic and racial minority communities disproportionately affected by COVID-19.

Read More

16 September 2020 NIH funds community engagement research efforts in areas hardest hit by COVID-19

Outreach will focus on COVID-19 awareness and education research, especially among African Americans, Hispanics/Latinos, and American Indians.

Read More

15 September 2020 NIH Launches antithrombotics trials in COVID-19 patients

The adaptive Phase III trials will assess whether various types and doses of blood thinners can prevent COVID-19 patients forming potentially fatal blood clots.

Read More

15 September 2020 Bridging the Gap at Warp Speed – Delivering Options for Preventing and Treating Covid-19

Operation Warp Speed (OWS), an effort of the U.S. Department of Health and Human Services and the Department of Defense in partnership with the private sector, is providing financial investment, scientific support, regulatory expertise, and logistic assistance to deliver vaccines, therapeutics, and diagnostics for SARS-CoV-2 to the American public as quickly as possible.

Read More

14 September 2020 NIH Launches Clinical Trials of Antithrombotic for COVID-19

Two of three planned adaptive phase 3 clinical trials evaluating the safety and effectiveness of varying types of blood thinners to treat adults diagnosed with COVID-19 have launched, according to an announcement by the National Institutes of Health (NIH).

Read More

14 September 2020 NIH ACTIV Initiative Launches Adaptive Clinical Trails of Blood-Clotting Treatments for COVID-19

The National Institutes of Health has launched two of three adaptive Phase 3 clinical trials evaluating the safety and effectiveness of varying types of blood thinners to treat adults diagnosed with COVID-19. Part of the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) initiative, these trials will be conducted at more than 100 sites around the world and will involve patients in various clinical settings — those who have not been hospitalized, those currently hospitalized and those discharged after hospitalization for moderate to severe disease.

Read More

14 September 2020 ACTIV-4 Antithrombotics Launched to Investigate Blood Thinners to Treat COVID-19 Patients

The National Institutes of Health has launched two of three adaptive Phase 3 clinical trials evaluating the safety and effectiveness of varying types of blood thinners to treat adults diagnosed with COVID-19. Part of the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) initiative, these trials will be conducted at more than 100 sites around the world and will involve patients in various clinical settings — those who have not been hospitalized, those currently hospitalized and those discharged after hospitalization for moderate to severe disease.

Read More

13 September 2020 NIH ACTIV Initiative Begins Adaptive Clinical Trials of Blood Clotting Treatments for COVID-19

Learn more about NIH’s ACTIV-4 clinical trials aimed at reducing blood clotting in patients with COVID-19 with NIH Director Dr. Francis Collins and NIH’s National Heart, Lung, and Blood Institute Director Dr. Gary Gibbons.

Read More

10 September 2020 NIH ACTIV initiative launches adaptive clinical trials of blood-clotting treatments for COVID-19

The National Institutes of Health has launched two of three adaptive Phase 3 clinical trials evaluating the safety and effectiveness of varying types of blood thinners to treat adults diagnosed with COVID-19. Part of the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) initiative, these trials will be conducted at more than 100 sites around the world and will involve patients in various clinical settings — those who have not been hospitalized, those currently hospitalized and those discharged after hospitalization for moderate to severe disease.

Read More

10 September 2020 Learner Team Plays Role in NIH COVID-19 Blood Clotting Treatment Trials

The University of Vermont (UVM) is participating in a major national research effort to evaluate the safety and effectiveness of varying types of blood thinners to treat adults diagnosed and hospitalized with COVID-19—the disease caused by SARS-CoV-2. The National Institutes of Health (NIH) announced the launch of two of three adaptive Phase 3 clinical trials September 10.

Read More

08 September 2020 NIH clinical trial explores use of convalescent plasma in at-risk outpatients with early COVID-19

Researchers supported by the National Institutes of Health have launched a key study to explore the safety and effectiveness of convalescent plasma in treating patients who have recently (within the last week) developed mild to moderate symptoms of COVID-19 disease. The study, which focuses on patients not yet hospitalized, comes on the heels of an announcement by the U.S. Food & Drug Administration (FDA) authorizing emergency use of convalescent plasma to help treat hospitalized patients with COVID-19.

Read More

01 September 2020 Event: Launching CONNECTS: Collaborating Network of Networks for Evaluating COVID-19 and Therapeutic Strategies

Topic: Launching CONNECTS (Collaborating Network of Networks for Evaluating COVID-19 and Therapeutic Strategies): A Partnership Between Research Triangle Institute, Vanderbilt University Medical Center, and the NHLBI. Date: Friday, September 11, 2020, 1:00-2:00 p.m. ET

Read More

13 August 2020 RTI researchers to help coordinate federal program seeking COVID-19 treatments

Federal health officials have tapped RTI International to join a collaboration tracking COVID-19’s ability to cause severe illness and the effectiveness of proposed treatments.

Read More

10 August 2020 Baylor Scott & White Research Institute enrolls first patients in NIH ACTIV-3 clinical trial

On Wednesday, August 5, in Dallas, just one day after the initiative was launched by the National Institutes of Health (NIH), Baylor Scott & White Research Institute enrolled the first patient in the world for the ACTIV-3 clinical trial. A second patient was enrolled the following day.

Read More

03 August 2020 4 former FDA commissioners: Blood plasma might be the covid-19 treatment we need

Blood plasma — also known as convalescent plasma — has been used as a therapy for infectious diseases for a century, including against the flu in 1918 as well as SARS, Ebola, meningitis and measles. While it doesn’t work for all infections, the idea is to use one person’s successful defense system of antibodies to bolster the immune response of a newly infected person.

Read More

30 July 2020 C3PO Clinical Trial

Michigan Medicine and three other medical centers receive $7 million for COVID-19 outpatient convalescent plasma therapy trial.

Read More

29 July 2020 COVID-19 trial to study convalescent plasma in outpatient setting

The Data Coordination Unit (DCU) in the Department of Public Health Sciences at the Medical University of South Carolina will take on the role of Data Coordinating Center for a $7 million national trial studying the role of convalescent plasma in mitigating the symptoms of COVID-19 in patients with mild illness and preventing the progression of the disease from mild to severe.

Read More

28 July 2020 Pitt Collaborative to Study Outpatient Convalescent Plasma

A team of University of Pittsburgh, Michigan Medicine, Medical University of South Carolina and Stanford Medicine researchers recently were awarded funds from the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services (HHS), totaling more than $7 million to collaboratively study the role of convalescent plasma in mitigating symptoms of COVID-19 in patients with mild illness and preventing the progression of the disease from mild to severe.

Read More

27 July 2020 Phase 3 clinical trial of investigational vaccine for COVID-19 begins

A Phase 3 clinical trial designed to evaluate if an investigational vaccine can prevent symptomatic coronavirus disease 2019 (COVID-19) in adults has begun.

Read More

24 July 2020 COVID-19 Therapeutics Prioritized for Testing in Clinical Trials

The ACTIV public-private partnership has evaluated and prioritized therapeutic agents with potential application for COVID-19; and selected numerous NIH-supported networks to launch clinical trials to test prioritized therapeutic candidates.

Read More

20 July 2020 CHOC Hematologist Appointed to National COVID-19 Therapy Evaluation Oversight Committee

Dr. Diane Nugent has been named co-chair of the Steering Committee for the National Heart, Lung, and Blood Institute (NHLBI) Collaborating Network of Networks for Evaluating COVID-19 and Therapeutic Strategies, or CONNECTS, which will coalesce projects into a national, coordinated effort. She will also serve on the Executive committee for CONNECTS to facilitate the rapid turnaround and implementation of these grants throughout the country.

Read More

15 July 2020 Launch Announcement: Collaborating Network of Networks for Evaluating COVID-19 and Therapeutic Strategies (CONNECTS)

The NHLBI’s Collaborating Network of Networks for Evaluating COVID-19 and Therapeutic Strategies (CONNECTS) is an important and innovative research effort. The goal of CONNECTS is to build on NHLBI’s existing clinical research networks across the nation and around the world to better understand the risk of severe illness from COVID-19 and to identify therapies that will slow or halt the disease progression and speed recovery.

Read More

13 July 2020 NHLBI's COVID-19 Research Strategy

Given the major impact of underlying heart, lung, and blood diseases and conditions on morbidity and mortality among patients with Coronavirus Disease 2019 (COVID-19), the NHLBI is pursuing a multi-pronged research strategy that leverages NHLBI-supported expertise, research, and infrastructure.

Read More